Prognostic prediction and immunotherapy response analysis of the fatty acid metabolism-related genes in clear cell renal cell carcinoma

被引:3
作者
Yao, Qinfan [1 ,2 ,3 ,4 ]
Zhang, Xiuyuan [1 ,2 ,3 ,4 ]
Wei, Chunchun [1 ,2 ,3 ,4 ]
Chen, Hongjun [1 ,2 ,3 ,4 ]
Xu, Qiannan [1 ,2 ,3 ,4 ]
Chen, Jianghua [1 ,2 ,3 ,4 ]
Chen, Dajin [1 ,2 ,3 ,4 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Kidney Dis Ctr, Qingchun Rd 79, Hangzhou 310003, Peoples R China
[2] Key Lab Kidney Dis Prevent & Control Technol, Hangzhou, Zhejiang, Peoples R China
[3] Zhejiang Univ, Inst Nephropathy, Hangzhou, Peoples R China
[4] Zhejiang Clin Res Ctr Kidney & Urinary Syst Dis, Hangzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
Fatty acid metabolism; ccRCC; Immune features; Prognostic model; Treatment; AEROBIC GLYCOLYSIS; LIPID-METABOLISM; TUMOR GLYCOLYSIS; OVARIAN-CANCER; THERAPY; SURVIVAL; HETEROGENEITY; METABOLOMICS; CHECKPOINT; INHIBITION;
D O I
10.1016/j.heliyon.2023.e17224
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Clear cell renal cell carcinoma (ccRCC) is a common urinary cancer. Although diagnostic and therapeutic approaches for ccRCC have been improved, the survival outcomes of patients with advanced ccRCC remain unsatisfactory. Fatty acid metabolism (FAM) has been increasingly recognized as a critical modulator of cancer development. However, the significance of the FAM in ccRCC remains unclear. Herein, we explored the function of a FAM-related risk score in the stratification and prediction of treatment responses in patients with ccRCC.Methods: First, we applied an unsupervised clustering method to categorize patients from The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) datasets into subtypes and retrieved FAM-related genes from the MSigDB database. We discern differentially expressed genes (DEGs) among different subtypes. Then, we applied univariate Cox regression analysis followed by least absolute shrinkage and selection operator (LASSO) linear regression based on DEGs expression to establish a FAM-related risk score for ccRCC.Results: We stratified the three ccRCC subtypes based on FAM-related genes with distinct overall survival (OS), clinical features, immune infiltration patterns, and treatment sensitivities. We screened nine genes from the FAM-related DEGs in the three subtypes to establish a risk pre-diction model for ccRCC. Nine FAM-related genes were differentially expressed in the ccRCC cell line ACHN compared to the normal kidney cell line HK2. High-risk patients had worse OS, higher genomic heterogeneity, a more complex tumor microenvironment (TME), and elevated expres-sion of immune checkpoints. This phenomenon was validated in the ICGC cohort.Conclusion: We constructed a FAM-related risk score that predicts the prognosis and therapeutic response of ccRCC. The close association between FAM and ccRCC progression lays a foundation for further exploring FAM-related functions in ccRCC.
引用
收藏
页数:14
相关论文
共 106 条
  • [1] Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy
    Abdel-Wahab, Ali F.
    Mahmoud, Waheed
    Al-Harizy, Randa M.
    [J]. PHARMACOLOGICAL RESEARCH, 2019, 150
  • [2] A Cancer Cell-Intrinsic GOT2-PPARδ Axis Suppresses Antitumor Immunity
    Abrego, Jaime
    Sanford-Crane, Hannah
    Oon, Chet
    Xiao, Xu
    Betts, Courtney B.
    Sun, Duanchen
    Nagarajan, Shanthi
    Diaz, Luis
    Sandborg, Holly
    Bhattacharyya, Sohinee
    Xia, Zheng
    Coussens, Lisa M.
    Tontonoz, Peter
    Sherman, Mara H.
    [J]. CANCER DISCOVERY, 2022, 12 (10) : 2414 - 2433
  • [3] Hypoxia, lipids, and cancer: surviving the harsh tumor microenvironment
    Ackerman, Daniel
    Simon, M. Celeste
    [J]. TRENDS IN CELL BIOLOGY, 2014, 24 (08) : 472 - 478
  • [4] Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma
    Atkins, Michael B.
    Tannir, Nizar M.
    [J]. CANCER TREATMENT REVIEWS, 2018, 70 : 127 - 137
  • [5] Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
    Auslander, Noam
    Zhang, Gao
    Lee, Joo Sang
    Frederick, Dennie T.
    Miao, Benchun
    Moll, Tabea
    Tian, Tian
    Wei, Zhi
    Madan, Sanna
    Sullivan, Ryan J.
    Boland, Genevieve
    Flaherty, Keith
    Herlyn, Meenhard
    Ruppin, Eytan
    [J]. NATURE MEDICINE, 2018, 24 (10) : 1545 - +
  • [6] Conserved pan-cancer microenvironment subtypes predict response to immunotherapy
    Bagaev, Alexander
    Kotlov, Nikita
    Nomie, Krystle
    Svekolkin, Viktor
    Gafurov, Azamat
    Isaeva, Olga
    Osokin, Nikita
    Kozlov, Ivan
    Frenkel, Felix
    Gancharova, Olga
    Almog, Nava
    Tsiper, Maria
    Ataullakhanov, Ravshan
    Fowler, Nathan
    [J]. CANCER CELL, 2021, 39 (06) : 845 - +
  • [7] Fatty acid synthase: A metabolic oncogene in prostate cancer?
    Baron, A
    Migita, T
    Tang, D
    Loda, M
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 2004, 91 (01) : 47 - 53
  • [8] Chemical inhibition of Acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells
    Beckers, Annelies
    Organe, Sophie
    Tinunermans, Leen
    Scheys, Katryn
    Peeters, Annelies
    Brusselmans, Koen
    Verhoeven, Guido
    Swinnen, Johannes V.
    [J]. CANCER RESEARCH, 2007, 67 (17) : 8180 - 8187
  • [9] The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma
    Bedke, Jens
    Albiges, Laurence
    Capitanio, Umberto
    Giles, Rachel H.
    Hora, Milan
    Ljungberg, Borje
    Marconi, Lorenzo
    Klatte, Tobias
    Volpe, Alessandro
    Abu-Ghanem, Yasmin
    Dabestani, Saeed
    Fernandez-Pello, Sergio
    Hofmann, Fabian
    Kuusk, Teele
    Tahbaz, Rana
    Powles, Thomas
    Bex, Axel
    [J]. EUROPEAN UROLOGY, 2023, 83 (01) : 10 - +
  • [10] Historical perspective of tumor glycolysis: A century with Otto Warburg
    Bononi, Giulia
    Masoni, Samuele
    Di Bussolo, Valeria
    Tuccinardi, Tiziano
    Granchi, Carlotta
    Minutolo, Filippo
    [J]. SEMINARS IN CANCER BIOLOGY, 2022, 86 : 325 - 333